Meining A, Morgner A, Miehlke S, Bayerdörffer E, Stolte M
Medizinische Klinik II, Klinikum rechts der Isar, Ismaninger Strasse 22, 81675 München, Germany.
Best Pract Res Clin Gastroenterol. 2001 Dec;15(6):983-98. doi: 10.1053/bega.2001.0253.
The results of recent investigations have suggested that the old hypothesis of an atrophy-metaplasia-dysplasia-carcinoma sequence in the stomach needs to be qualified. The most common cause of intestinal metaplasia is Helicobacter pylori gastritis. The consequence of this intestinal metaplasia is focal atrophy. Helicobacter pylori infection may also trigger an autoimmune gastritis of the corpus mucosa, with atrophy and intestinal metaplasia. Most intestinal metaplasias are only 'paracancerous' but not 'precancerous' lesions. Diffuse gastric carcinomas, such as the signet ring cell carcinoma, arise independently of intestinal metaplasia. Histogenetically, numerous carcinomas of the stomach are primarily of the gastric type, and may secondarily change into the intestinal type.High-grade intra-epithelial neoplasias (dysplasias) detected during the biopsy-based diagnostic work-up appear to be a marker for carcinoma and must, therefore, be removed endoscopically. The detection of intestinal metaplasia in routinely obtained biopsy material is subject to sampling error and is, therefore, not a suitable marker for an increased risk of a gastric carcinoma developing. As an alternative, the concept of gastritis of the carcinoma phenotype, which is more frequently found in early gastric carcinomas and in the relatives of gastric carcinoma patients, has been developed. In this concept, the diffuse parameters of grade and activity of the gastritis in the antrum and corpus, which are independent of sampling error, are subjected to a comparative analysis. A risk gastritis of the carcinoma phenotype is diagnosed when the grade and activity of the gastritis in the corpus are at least equally as pronounced as in the antrum. Currently, this concept is being tested in a prospective ongoing study. Future studies must show whether, and if so which, immunohistochemical or molecular-genetically detectable changes can be applied as risk markers in the diagnostic work-up. Helicobacter pylori eradication probably does not lead to complete regression of the intestinal metaplasia and ensuing focal atrophy. However, eradication of H. pylori does lead to the normalization of changes that can lead to mutations of the stem cells of the gastric mucosa (free radicals, nitric oxide, cell proliferation and vitamin C secretion).
近期调查结果表明,胃萎缩-化生-发育异常-癌序列的旧假说是需要修正的。肠化生最常见的原因是幽门螺杆菌胃炎。这种肠化生的后果是局灶性萎缩。幽门螺杆菌感染也可能引发胃体黏膜的自身免疫性胃炎,伴有萎缩和肠化生。大多数肠化生仅是“癌旁”而非“癌前”病变。弥漫性胃癌,如印戒细胞癌,独立于肠化生发生。从组织发生学上看,众多胃癌主要为胃型,可能继发转变为肠型。在基于活检的诊断检查中检测到的高级别上皮内瘤变(发育异常)似乎是癌症的标志物,因此必须通过内镜切除。在常规获取的活检材料中检测到肠化生存在抽样误差,所以不是胃癌发生风险增加的合适标志物。作为替代方案,已提出癌表型胃炎的概念,其在早期胃癌和胃癌患者亲属中更常见。在这个概念中,对胃窦和胃体胃炎的分级和活动度等不受抽样误差影响的弥漫性参数进行比较分析。当胃体胃炎的分级和活动度至少与胃窦一样明显时,诊断为癌表型风险胃炎。目前,这一概念正在一项前瞻性正在进行的研究中进行测试。未来的研究必须表明,是否以及哪些免疫组化或分子遗传学可检测到的变化能够作为诊断检查中的风险标志物。根除幽门螺杆菌可能不会导致肠化生及随之而来的局灶性萎缩完全消退。然而,根除幽门螺杆菌确实会使可能导致胃黏膜干细胞突变的变化(自由基、一氧化氮、细胞增殖和维生素C分泌)恢复正常。